Drugs

Article	Citations
Prevention and Treatment of Monkeypox	342
BNT162b2 mRNA COVID-19 Vaccine: First Approval	237
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update	206
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin	198
Pharmaco-Immunomodulatory Therapy in COVID-19	196
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences	195
Inclisiran: First Approval	188
Lumasiran: First Approval	178
Remdesivir: First Approval	172
Nirmatrelvir Plus Ritonavir: First Approval	168
Casimersen: First Approval	154
Aducanumab: First Approval	137
Acute Pancreatitis: Diagnosis and Treatment	132
Sotorasib: First Approval	123
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile I	107
Risdiplam: First Approval	105
Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update	101
TRPV1-Targeted Drugs in Development for Human Pain Conditions	101
Setmelanotide: First Approval	101
Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing	97
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis	93
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects	91
Selpercatinib: First Approval	90
Belantamab Mafodotin: First Approval	90
Bulevirtide: First Approval	89

Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?	88
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer	84
Orelabrutinib: First Approval	84
Inhaled Liposomal Antimicrobial Delivery in Lung Infections	82
Nivolumab Plus Relatlimab: First Approval	79
REGN-EB3: First Approval	77
Amivantamab: First Approval	76
Lonafarnib: First Approval	75
Fabry Disease: The Current Treatment Landscape	74
HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety	74
Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review	71
Deucravacitinib: First Approval	70
Decitabine/Cedazuridine: First Approval	70
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder	69
Pralsetinib: First Approval	69
Remimazolam: A Review in Procedural Sedation	68
Belzutifan: First Approval	67
Savolitinib: First Approval	66
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases	65
Faricimab: First Approval	64
Inebilizumab: First Approval	64
Tisotumab Vedotin: First Approval	60
MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19	60
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations	60
Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections	58
Casirivimab/Imdevimab: First Approval	58
Disitamab Vedotin: First Approval	57
Molnupiravir: First Approval	57
Vutrisiran: First Approval	57
Abrocitinib: First Approval	57
Infigratinib: First Approval	55
Telitacicept: First Approval	55
Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain	55
Efgartigimod: First Approval	54
Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis	54
Trilaciclib: First Approval	54
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma	54
Contezolid: First Approval	53
Current Status of Clinical Trials on Tau Immunotherapies	53
Targeting AMPK by Statins: A Potential Therapeutic Approach	53
Cadonilimab: First Approval	52
Tebentafusp: First Approval	52
Loncastuximab Tesirine: First Approval	51
Dostarlimab: First Approval	51
Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals	50
Lecanemab: First Approval	50
Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections	50
Pegcetacoplan: First Approval	49
Lurbinectedin: First Approval	49
Filgotinib: First Approval	49

Umbralisib: First Approval	48
Ocrelizumab: A Review in Multiple Sclerosis	48
Tirzepatide: First Approval	48
Naxitamab: First Approval	47
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective	46
Daprodustat: First Approval	46
Envafolimab: First Approval	46
Odevixibat: First Approval	46
Management of Thrombotic Complications in COVID-19: An Update	45
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics	44
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations	44
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update	43
The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review	43
Therapeutic Options in Hereditary Optic Neuropathies	43
Tremelimumab: First Approval	43
Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents	43
Anifrolumab: First Approval	42
Givosiran: A Review in Acute Hepatic Porphyria	42
Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics	42
Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon	41
Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs	41
Voclosporin: First Approval	41
Regdanvimab: First Approval	41
Fuzuloparib: First Approval	41
Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review	40
Functional Dyspepsia: Diagnostic and Therapeutic Approaches	40
Lazertinib: First Approval	40
Chronic Pancreatitis: Epidemiology, Diagnosis, and Management Updates	40
Mavacamten: First Approval	40
Tezepelumab: First Approval	40
Sotrovimab: First Approval	39
Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists	39
Mosunetuzumab: First Approval	38
Satralizumab: First Approval	38
Nirsevimab: First Approval	38
Spesolimab: First Approval	38
Teclistamab: First Approval	38
Mirvetuximab Soravtansine: First Approval	37
Adagrasib: First Approval	37
Asciminib: First Approval	36
Evinacumab: First Approval	36
Pamiparib: First Approval	36
Donafenib: First Approval	36
Vadadustat: First Approval	36
Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy	36
Tixagevimab + Cilgavimab: First Approval	35
Daridorexant: First Approval	35
Avacopan: First Approval	35
Melphalan Flufenamide (Melflufen): First Approval	35
Valoctocogene Roxaparvovec: First Approval	35
Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?	35
Etranacogene Dezaparvovec: First Approval	34
Finerenone: First Approval	34
Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents	34
Olverembatinib: First Approval	34
Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions	34
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A	34
Vericiguat: First Approval	34
Mobocertinib: First Approval	33
Delandistrogene Moxeparvovec: First Approval	33
Are New Antiretroviral Treatments Increasing the Risk of Weight Gain?	33
REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study	32
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes	32
Ozoralizumab: First Approval	32
Ansuvimab: First Approval	32
Maralixibat: First Approval	31
Margetuximab: First Approval	31
Ibrexafungerp: First Approval	31
Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease	31
Oliceridine: First Approval	31
Androgenetic Alopecia: Therapy Update	31
Futibatinib: First Approval	31
Atogepant: First Approval	31
Tapinarof Cream 1%: First Approval	30
Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)	30
Difelikefalin: First Approval	29
Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa	29
Post-Thoracotomy Pain: Current Strategies for Prevention and Treatment	29
Belumosudil: First Approval	28
Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections	28

Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis	28
Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC	28
Tofersen: First Approval	28
Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry	28
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?	27
Lenacapavir: First Approval	27
Oteseconazole: First Approval	27
Hetrombopag: First Approval	27
Tralokinumab: First Approval	26
Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies	26
Pacritinib: First Approval	26
Enarodustat: First Approval	26
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence	26
Secukinumab: A Review in Psoriatic Arthritis	26
Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review	25
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars	25
Nemolizumab: First Approval	25
Ganaxolone: First Approval	25
Deprescribing Opioids in Chronic Non-cancer Pain: Systematic Review of Randomised Trials	25
Fostemsavir: First Approval	25
Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets	25
New Agents in Development for Sepsis: Any Reason for Hope?	25
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?	25
Pimitespib: First Approval	24
Maribavir: First Approval	24
Ocular Toxicity of Targeted Anticancer Agents	23
Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside	23
Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis	23
Dexamethasone Intracanalicular Insert: A Review in Treating Post-Surgical Ocular Pain and Inflammation	23
Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease	23
The Expanding Role of the COX Inhibitor/Opioid Receptor Agonist Combination in the Management of Pain	23
Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives	23
Ponesimod: First Approval	23
Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients	23
The Potential Role of Clinical Metagenomics in Infectious Diseases: Therapeutic Perspectives	23
The Role of Vitamin D in Health and Disease: A Narrative Review on the Mechanisms Linking Vitamin D with Disease and the Effects of Supplementation	22
Triheptanoin: First Approval	22
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries	22
Furmonertinib: First Approval	22
Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia	22
Omaveloxolone: First Approval	22
Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review	22
Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors	21
Avatrombopag: A Review in Thrombocytopenia	21
Benefits and Harms of ‘Smart Drugs’ (Nootropics) in Healthy Individuals	21
Tafasitamab: First Approval	21
Contemporary Management of Dyslipidemia	21
Serplulimab: First Approval	21
Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity	21
Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent	21
Olipudase Alfa: First Approval	20
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis	20
The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density	20
Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?	20
Bimekizumab for the Treatment of Psoriasis	20
Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020	20
Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?	20
New Topical Therapies in Development for Atopic Dermatitis	20
Estetrol/Drospirenone: A Review in Oral Contraception	20
The Struggle to End a Millennia-Long Pandemic: Novel Candidate and Repurposed Drugs for the Treatment of Tuberculosis	20
A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease	19
Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer	19
Bupivacaine/Meloxicam Prolonged Release: A Review in Postoperative Pain	19
Efficacy of Montelukast in Allergic Rhinitis Treatment: A Systematic Review and Meta-Analysis	19
Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting	19
Baricitinib for the Treatment of Alopecia Areata	18
Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer	18
Budesonide/Glycopyrronium/Formoterol: A Review in COPD	18
Avalglucosidase alfa: First Approval	18
Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease	18
Ozanimod: A Review in Ulcerative Colitis	18
Gefapixant: First Approval	18
Pathophysiology and Management of Variceal Bleeding	18
Vosoritide: First Approval	18
Penpulimab: First Approval	18
Olanzapine/Samidorphan: First Approval	18
Tirbanibulin: First Approval	18
Glofitamab: First Approval	18
Personalized Multimorbidity Management for Patients with Type 2 Diabetes Using Reinforcement Learning of Electronic Health Records	18
Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations	17
Pharmacologic Management of Persistent Pain in Cancer Survivors	17
Surufatinib: First Approval	17
Atezolizumab: A Review in Extensive-Stage SCLC	17
Sugemalimab: First Approval	17
Cannabis-Based Medicines and Medical Cannabis in the Treatment of Nociplastic Pain	17
Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome	17
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification	17
Rezafungin: First Approval	16
Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases	16
Drug Treatment of Cluster Headache	16
Valemetostat Tosilate: First Approval	16
Nadofaragene Firadenovec: First Approval	16
Targeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress	16
Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review	16
Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria	16